Human Oncology & Pathogenesis Program
The James Fagin Lab
The focus of our work is to understand the pathogenesis and the biology of thyroid cancers with the goal of identifying new molecular-based therapies. Thyroid cancer is the most common endocrine malignancy. Exposure to radiation during childhood confers increased predisposition to this disease. Our lab has been instrumental in characterizing many of the somatic genetic changes associated with thyroid tumor initiation and progression in both radiation-induced and sporadic thyroid cancer, and in defining the functional consequences using in vitro and in vivo experimental models.
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale AJ, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discovery 2013, May;3(5):520-33.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. Engl J Med 2013; Feb 14;368(7):623-32.
Chakravarty D, Santos E, Ryder M, Knauf J, Liao XH, West B, Bollag G, Kolesnick R, Thin T, Rosen N, Zanzonico P, Larson S, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore RAI incorporation in murine thyroid cancers with conditional BRAF activation. J Clin Invest. 2011 121(12):4700-11.
Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A. 2011 Jan 10 108(4):1615-20.
Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo V, Mitsutake S, Kimura E, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA. Endogenous Expression Of HrasG12V Induces Developmental Defects and Neoplasms with Copy Number Imbalances Of The Oncogene. Proc. Natl Acad Sci USA, 2009 12;106(19):7979-84.
James A. Fagin, MD
Chief, Endocrinology Service, Department of Medicine, Memorial Hospital
- Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.
- MD, University of Buenos Aires School of Medicine (Argentina)
- President, American Thyroid Association (2012)
- UK Clinical Endocrinology Trust Medal Lecture Award (2011)
- Sydney Ingbar Award, American Thyroid Association (2008)
- Merck Prize, European Thyroid Association Award (2007)
- Association of American Physicians Award (2001)
- American Society of Clinical Investigation Award (1998)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James A. Fagin discloses the following relationships and financial interests:
Intellectual Property Rights
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.